Cyclopropylamine compound as well as preparation method and application thereof in antiviral aspect
By developing and optimizing the cipropylamine compound DDP-38003 and its derivatives, the problems of limited effects and high cytotoxicity of existing antiviral drugs on a variety of viruses have been solved, and effective inhibition of coronavirus and yellow fever viruses have been achieved. Reduced the toxicity of the drug and demonstrated its potential value in the antiviral field.
Patent Information
- Application Number
- CN202410960722.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-07-18
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
AI Technical Summary
Existing antiviral drugs have shown limited effects on a variety of viruses, especially coronaviruses and yellow fever viruses, and have high cytotoxicity, making it difficult to effectively inhibit viral replication and reactivation.
A class of cipropylamine compounds DDP-38003 and their derivatives were developed. Compounds with excellent antiviral activity were discovered through structural optimization, which were used as potential components of antiviral drugs, combined with pharmaceutical salts, enantiomers, and non- Enantiomers or optical isomers are prepared into pharmaceutical compositions to improve efficacy and reduce toxicity.
The compounds exhibited ideal antiviral activity, had significant inhibitory effects on coronavirus and yellow fever viruses, and had low cytotoxicity, with potential value for developing as antiviral drugs.
Smart Images

Figure CN118908915A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and in particular, relates to a cyclopropylamine compound and a preparation method thereof and an application thereof in antiviral treatment. Background Art
[0002] Lysine-specific demethylase 1 (LSD1 / KDM1A) is a demethylase that targets cellular proteins and is involved in a variety of cellular processes, including signal transduction, transcriptional regulation, chromatin remodeling, cell differentiation and proliferation [F1000Res., 2017, 6: 2016.]. LSD1 also plays an important role in viral infection. Thomas M. Kristie et al. found that LSD1 is essential for the initial stage of herpes simplex virus (HSV) infection, and the LSD1 inhibitor OG-L002 (IC50 = ~0.02 μM) can inhibit viral replication and reactivation [mBio., 2013, 4 (1): e00558-12.]; Alejandra Loyola et al. found that LSD1 can cooperate with the enzyme SetDB1 to activate hepatitis B virus (HBV) chromatin to promote HBV transcription [Sci. Rep., 2016, 6: 25901]; Naoki Sakane et al. found that LSD1 can activate HIV transcription in latently infected T cells by specifically demethylating the viral Tat protein, and the compound phenelzine (IC50 = 300 μM) with LSD1 inhibitory activity can inhibit TNFα-mediated gene expression activation [PLoS Pathog., 2011, 7(8): e1002184.]; Jonathan et al. found that the LSD1 inhibitor TCP and its derivatives (IC50 = 1.9 μM) can effectively inhibit the replication of flaviviruses, including dengue virus, West Nile virus, yellow fever virus and hepatitis C virus, and in particular, can inhibit the replication of hepatitis C virus RNA by acting on host proteins (0.3-0.5 μM level) [US: 20140256742A1, 214-09-11.].
[0003] Based on the above research, our research team screened LSD1 inhibitors for antiviral activity and found that the LSD1 inhibitor DDP-38003 has clear in vitro anti-coronavirus (HCoV-OC43, IC50 = 1.59μM, CN113750095A,) and anti-flavivirus activity (ZIKV, IC50 = 3.92μM, CN113797199A), as well as low cytotoxicity (BHK21 cells and HEK293T cells, CC50>100μM). This study used DDP-38003 as the lead compound and discovered a class of cyclopropyl skeleton compounds with excellent antiviral activity through systematic structural optimization. This class of compounds has the potential value of being developed as antiviral drugs. Summary of the invention
[0004] One of the objects of the present invention is to provide a group of cyclopropylamine compounds, their pharmaceutically acceptable salts, enantiomers, diastereomers, optical isomers or racemates.
[0005] Another object of the present invention is to provide a method for synthesizing the cyclopropylamine compounds.
[0006] Another object of the present invention is to provide a composition containing the cyclopropylamine compound, its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate.
[0007] Another object of the present invention is to provide a pharmaceutical composition or pharmaceutical preparation using the cyclopropylamine compound, its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate as an active ingredient, and the use of the pharmaceutical composition in the preparation of antiviral drugs.
[0008] Definition of terms
[0009] The terms used in the description of the present invention herein are only for describing specific embodiments and are not intended to limit the present invention. The nomenclature used herein and the laboratory operations in the organic chemistry, medicinal chemistry, and biology described herein are well known and commonly used in the art. Unless otherwise mentioned, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this art belongs.
[0010] As used in the description of the embodiments of the present invention and the appended claims, the singular forms "a", "an", "the", and "its" refer to both the singular and the plural, unless the context clearly dictates otherwise. For example, a compound includes one or more than one compound.
[0011] Technical Theme 1
[0012] The present invention provides a cyclopropylamine compound having a structure as shown in Formula I, and a pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate thereof:
[0013]
[0014] Wherein, X represents C or N;
[0015] R 1 is one or more, independently representing H, halogen, cyano, NO2, C1-C5 alkyl, 1-3 halogenated C1-C5 alkyl, C1-C5 alkoxy, 1-3 halogenated C1-C5 alkoxy, C2-C5 alkenyl, C2-C5 alkynyl, R a Substituted or unsubstituted phenyl, Ra Substituted or unsubstituted 5-6 membered cycloalkyl, R a Substituted or unsubstituted 5-6 membered heteroaryl, R a A substituted or unsubstituted 5-6 membered heterocyclic group containing 1-3 groups selected from N, O and S;
[0016] R a is one or more, independently representing halogen, C1-C5 alkyl, 1-3 halogenated C1-C5 alkyl, C1-C5 alkoxy, 1-3 halogenated C1-C5 alkoxy;
[0017] R 2 Represents NR x R y , C1-C5 carboxyl, C1-C5 ester,
[0018] R x Selected from H, C1-C5 alkyl;
[0019] R y Selected from H, C1-C5 alkyl, C1-C3 sulfonyl, C1-C5 carbonyl, C1-C5 substituted or unsubstituted aminoacyl.
[0020] As some preferred embodiments of the present invention, the halogen is selected from F, Cl, Br, I;
[0021] The C1-C5 alkyl group is selected from —CH3, —CH2CH3, —CH(CH3)2, —(CH2)2CH3, —(CH2)3CH3, —CH2CH(CH3)2, —C(CH3)3, —CH(CH3)CH2CH3, —(CH2)4CH3, —CH(CH3)(CH2)2CH3, —CH(CH2CH3)2, —CH2C(CH2)3, —CH2CH(CH3)CH2CH3, —C(CH3)2CH2CH3, —CH(CH3)CH(CH3)2, —(CH2)2CH(CH3)2;
[0022] The C1-C5 alkoxy group is selected from -OCH3, -OCH2CH3, -OCH(CH3)2, -O(CH2)2CH3, -O(CH2)3CH3, -OCH2CH(CH3)2, -OC(CH3)3, -OCH(CH3)CH2CH3, -O(CH2)4CH3, - OCH(CH3)(CH2)2CH3, —OCH(CH2CH3)2, —OCH2C(CH2)3, —OCH2CH(CH3)CH2CH3, —OC(CH3)2CH2CH3, —OCH(CH3)CH(CH3)2, —O(CH2)2CH(CH3)2;
[0023] The C2-C5 alkenyl group is selected from -CHCH2, -CH2CHCH2, -CHCHCH3, -CH2CH CHCH3, -CHCHCH2CH3, -CH2CH2CHCH2, -CH(CH3)CHCH2, -CH2CHCH CH2CH3, -CHCHCH2CH2CH3, -CH2CH2CHCHCH3, -CH2CH2CHCHCH3, -CH2CH2CH2CHCH3, -CH2CH2CH2CHCH2, -CH(CH3)CHCHCH3;
[0024] The C2-C5 alkynyl group is selected from -CCH, -CCCH3, -CH2CCH, -CCCH2CH3,
[0025] ―CH2CCCH3, ―CH2CH2CCH, ―CCCH2CH2CH3, ―CH2CCCH2CH3, ―CH2CH2CCCH3, ―CH2CH2CH2CCH, ―CH(CH3)CCCH3, ―CH(CH3)CCH;.
[0026] The 5-6 membered cycloalkyl group is selected from cyclohexyl and cyclopentyl;
[0027] The 5-6 membered heteroaryl group is selected from pyridine, furan, pyrrole, thiophene, and thiazole;
[0028] The 5-6 membered heterocyclic group is selected from piperidine, morpholine, and piperazine;
[0029] C1-C5 carboxyl is selected from: -C(O)OH, -CH2C(O)OH, -(CH2)2C(O)OH, -(CH2)3C(O)OH, -(CH2)4C(O)OH;
[0030] The C1-C5 ester group is selected from: -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9, -CH2C(O)OCH3, -CH2C(O)OC2H5, -CH2C(O)OC3H7, -C2H4C(O)OCH3, -C2H4C(O)OC2H5, -C3H6C(O)OCH3;
[0031] C1-C3 sulfonyl is selected from the group consisting of sulfonyl, methylsulfonyl, ethylsulfonyl, and propylsulfonyl;
[0032] C1-C5 carbonyl is selected from: -C(O)CH3, -C(O)C2H5, -C(O)C3H7, -C(O)C4H9, CH2C(O)CH3, -CH2C(O)C2H5, -CH2C(O)C3H7, -(CH2)2C(O)CH3, -(CH2)2C(O)C2H5 or -(CH2)3C(O)CH3;
[0033] The C1-C5 substituted or unsubstituted amine acyl group is selected from: -C(O)NH2, -C(O)NHCH3, -C(O)NH C2H5, -C(O)NHC3H7, -C(O)NHC4H9, -C(O)N(CH3)2, -C(O)N(CH2CH3)2.
[0034] As some preferred embodiments of the present invention, the R 1 Selected from H, Br, F, Cl, CF3, CH3, CH2CH3, OCF3, OCH3, NO2, CN,
[0035]
[0036] As some preferred embodiments of the present invention, the R 2 Selected from COOH, C(O)OCH2, NH2, NHCH3, N(CH3)2,
[0037] In some preferred embodiments of the present invention, the cyclopropylamine compound is selected from the following:
[0038]
[0039]
[0040]
[0041] As used herein, "pharmaceutically acceptable salts" refer to salts that retain the desired biological activity of the target compound and exhibit minimal undesirable toxicological effects. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of the compounds of the present invention with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable bases include salts prepared from inorganic bases and organic bases, and the salts of the inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganic salts, manganous salts, potassium salts, sodium salts, zinc salts, etc. The salts of the organic non-toxic bases include salts of primary amines, secondary amines and tertiary amines, including substituted amines and cyclic amines. For example: N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxocobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, guanidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid or nitric acid, and the like; organic acids such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)-benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectinic acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, aminosulfonic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalene disulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptonic acid, glycerophosphate, aspartic acid, sulfosalicylic acid, etc., including salts formed by sodium, potassium, magnesium, lithium, aluminum, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine.
[0042] As used herein, "isomers" refers to the ability of compounds of the invention to exist as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, single diastereomers, geometric isomers, etc., where the compounds of Formula I contain one or more asymmetric centers and / or double bonds. These compounds may be represented by the symbols "R" or "S," depending on the configuration of substituents around the stereogenic carbon atom, and may also be represented by the symbols "Z" or "E," depending on the arrangement of substituents around the carbon-carbon double bond, or the substituents around the carbon-carbon double bond may be referred to as "cis" or "trans." The compounds disclosed herein may exist as tautomers, and both tautomeric forms are intended to be included within the scope of the invention, even if only one tautomeric structure is depicted, such as imine-enamine tautomers, etc.
[0043] As some preferred embodiments of the present invention, the pharmaceutically acceptable salt is selected from hydrochloride, phosphate, methanesulfonate, sulfate or malate.
[0044] Technical Theme 2
[0045] The present invention also provides a method for synthesizing the cyclopropylamine compounds shown in Formula I. Although the compounds of the present invention can be prepared by the following method, the conditions of the method, such as reactants, solvents, acids, bases, the amount of the compounds used, reaction temperature, reaction time, etc., are not limited to the following description. The compounds of the present invention can also be conveniently prepared by combining various synthetic methods described in this specification or known to those skilled in the art, and those skilled in the art can easily perform the above combination.
[0046] Route 1
[0047]
[0048] Step a: Compound (±)-4 and R 1 The substituted benzoic acid was refluxed in oxalyl chloride, DMF and DCM for 5-8 h, and then DIEA was added to react in THF overnight to obtain compound (±)-5;
[0049] Step b: reacting with R-substituted benzoic acid under PyBOP condensing agent and alkaline conditions overnight to obtain compound (±)-5;
[0050] Step c: Compound (±)-5 is dissolved in methanol, and the Boc protecting group is removed in the presence of hydrochloric acid and ether to obtain the target compound (±)-1-2;
[0051] Route 2
[0052]
[0053] Step a: Add paraformaldehyde and glacial acetic acid to a methanol solution of compound (±)-2d, reflux and stir for 1-2 hours, cool and add sodium cyanoborohydride, and cook at room temperature for 3-6 hours;
[0054] Step b: Compound (±)-2d and R 2 Substituted acyl chloride or sulfonyl chloride is condensed under alkaline conditions to prepare compound (±)-3.
[0055] Route 3
[0056]
[0057] Step a: Compound (±)-6 is subjected to hydrogenation reduction to obtain compound (±)-7;
[0058] Step b: Compound (±)-7 is condensed with 4-bromobenzoyl chloride to obtain the target compound (±)-3j;
[0059] Step c: To a solution of (±)-3j in tetrahydrofuran and water was added lithium hydroxide and stirred at room temperature overnight.
[0060] Technical Theme 3
[0061] The present invention provides a pharmaceutical composition, which comprises a cyclopropylamine compound represented by formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
[0062] As used herein, "pharmaceutical composition" contains a therapeutically effective amount of the polysubstituted benzoheterocyclic compound of formula I or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, prepared in the form of tablets, capsules, granules, powders, suspensions, emulsions, powders, solutions, gels, syrups, pills, tinctures, wine preparations, decoctions, lozenges, mixtures, suppositories, injections, inhalants or sprays, etc. The pharmaceutical composition preferably contains 0.1% to 99.5% by weight of the polysubstituted benzoheterocyclic compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient, and more preferably contains 0.5% to 99.5% by weight of the active ingredient.
[0063] As used herein, "pharmaceutically acceptable carriers or excipients" include: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, colorants, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants and buffers. Those skilled in the art will understand that certain pharmaceutically acceptable excipients can be used in more than one function and in alternative functions, depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation. For example, when used for oral administration, oral preparations such as tablets, capsules, granules and pills can be prepared, containing fillers (e.g., sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as corn starch, potato starch, dextrin and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium; gum arabic; dextran; silicate derivatives such as magnesium aluminum metasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; sulfate derivatives such as calcium sulfate, etc.), binders (e.g., gelatin, polyvinyl pyrrolidone and polyethylene glycol), disintegrants (e.g., cellulose derivatives such as sodium carboxymethyl cellulose, polyvinyl pyrrolidone), lubricants (e.g., talc, calcium stearate, magnesium stearate, spermaceti, boric acid, sodium benzoate, leucine), stabilizers (methyl parahydroxybenzoate, propyl parahydroxybenzoate, etc.), flavoring agents (e.g., commonly used sweeteners, acidulants and spices, etc.). When used for parenteral administration, an injection can be prepared, including sterile powder for injection and solvent for injection, and the carrier or excipient used includes sterile water, Ringer's solution and isotonic sodium chloride solution, and suitable additives such as antioxidants, buffers and antibacterial agents can also be added according to the properties of the drug. When used for rectal administration, the drug can be prepared into suppositories, etc. When used for pulmonary administration, the drug can be prepared into inhalants or sprays, etc. There are many resources available to those skilled in the art, which describe pharmaceutically acceptable excipients and can be used to select suitable pharmaceutically acceptable excipients, such as books such as "Remington's Pharmaceutical Encyclopedia", "Chinese Pharmaceutical Annals", and "Pharmaceutics".
[0064] The present invention can be administered by any suitable method known in the art, for example, orally, intravenously, intraperitoneally, intramuscularly, topically, transdermally, ocularly, nasally, by inhalation, subcutaneously, intramuscularly, buccally, sublingually, and rectal administration, and the compound as described above can be administered in any amount of 1 μg to 2000 mg / kg of the subject's body weight, for example, 1 μg to 1000 mg / kg body weight / day, 50 μg to 1000 mg / kg body weight / day, 100 μg to 1000 mg / kg body weight / day, 1 to 500 mg / kg body weight / day, 2 to 200 mg / kg body weight / day, and 5 to 100 mg / kg body weight / day. In some embodiments of the present invention, the compound as described above can be administered 4 times a day, 3 times a day, 2 times a day, 1 time a day, 1 time every two days, 1 time a week, or other intervals, and the dosage regimen as described above can be repeated weekly or monthly as appropriate. In the present invention, the dosage of the compound can be adjusted according to factors such as the severity of the patient's or subject's condition, age, weight, gender, administration method, and course of treatment.
[0065] The compounds of the present invention can be used alone, or in combination with one or more other active ingredients for the treatment, prevention, inhibition or improvement of a disease or condition, wherein the combined use of the drugs is safer or more effective than the use of any one drug alone. Such other drugs can be administered simultaneously or sequentially with the compounds of the present invention in the manner and amount commonly used therefor. When the compounds of the present invention are used simultaneously with one or more other drugs, a pharmaceutical composition containing the other drugs and the compounds of the present invention in a unit dosage form is preferred, particularly in combination with a pharmaceutically acceptable carrier. However, combined therapy can also include treatment with the compounds of the present invention and one or more other drugs in different overlapping schedules. It can also be expected that when used in combination with one or more other active ingredients, the compounds of the present invention and other active ingredients can be used in lower doses than when each is used alone. Therefore, in addition to the compounds of the present invention, the pharmaceutical compositions of the present invention also include those compositions containing one or more other active ingredients.
[0066] Technical Theme 4
[0067] The present invention also provides the use of the cyclopropylamine compound shown in formula I or a pharmaceutically acceptable salt thereof in the preparation of antiviral drugs.
[0068] In some embodiments, the antiviral is selected from anti-coronavirus, anti-dengue virus, anti-Zika virus, anti-Ebola virus, or anti-influenza virus.
[0069] Advantageous Effects of the Invention
[0070] The compound developed by the present invention has been verified to have ideal antiviral activity and is expected to become a potential antiviral drug. DETAILED DESCRIPTION
[0071] The present invention is described below in conjunction with specific examples, which are not intended to limit the scope of the present invention, but provide guidance for those skilled in the art to prepare and use the compounds, compositions and methods of the present invention. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.
[0072] The chemical names of the compounds described in this application generally follow the principles of IUPAC nomenclature.
[0073] Some of the compounds in this example were synthesized by the following route:
[0074] Route 1
[0075]
[0076] Compound (±)-4 can be synthesized by referring to the literature method (J Am Chem Soc. 2010; 132(19): 6827-6833.), and then compound (±)-5 can be prepared by reacting with benzoic acid. The condensation method can be selected by preparing benzoyl chloride with oxalyl chloride and then condensing with (±)-4 under alkaline conditions; or reacting with benzoic acid under alkaline conditions in the presence of PyBOP condensation agent. Compound (±)-5 is dissolved in methanol, and the Boc protecting group is removed in the presence of hydrochloric acid and ether to obtain the target compound (±)-1-2.
[0077] Route 2
[0078]
[0079] Compound (±)-2d can be subjected to reductive amination reaction or condensation with acyl chloride under alkaline conditions to obtain compound (±)-3.
[0080] Route 3
[0081]
[0082] Compound (±)-6 can be synthesized by referring to the method in the literature (J Am Chem Soc. 2010; 132(19): 6827-6833.), and compound (±)-6 is reduced by hydrogenation to obtain compound (±)-7. Compound (±)-7 is condensed with 4-bromobenzoyl chloride to obtain the target compound (±)-3j. Compound (±)-3j is hydrolyzed under alkaline conditions to obtain the target compound (±)-3k.
[0083] Specific compounds are described in detail below.
[0084] Example 1 trans-N-(4-(-2-aminocyclopropyl)phenyl)-4-morpholinylbenzamide ((±)-1a)
[0085] At room temperature, oxalyl chloride (2.5 mmol) and N,N-dimethylformamide solution (10 μL) were added to a solution of the corresponding 4-morpholinebenzoic acid (0.5 mmol) in anhydrous dichloromethane. The mixture was refluxed for 6.5 h and concentrated. Then, a solution of 4 (0.55 mmol) and N,N-diisopropylethylamine (1 mmol) in anhydrous tetrahydrofuran was added at room temperature. The mixture was stirred at the same temperature overnight, quenched with water, extracted with dichloromethane, dried over magnesium sulfate, filtered, and the filtrate was concentrated. The mixture was purified by column chromatography (dichloromethane: methanol = 20:1) to obtain a yellow solid (±)-5.
[0086] At room temperature, a 4M hydrochloric acid solution in dioxane (2 mL) was added to a methanol solution of (±)-5, and the mixture was stirred overnight at the same temperature. The product was purified by thin layer chromatography (dichloromethane: methanol: ammonia water = 20:1:0.1) to obtain the product in the form of free amine, which was placed in a small amount of methanol and added with a 2M hydrochloric acid solution in ether to precipitate the salt, namely (±)-1a (yield 57%). 1 H NMR (600MHz, DMSO) δ9.97 (s, 1H), 8.59 (s, 3H), 7.90 (d, J = 8.7Hz, 2H), 7.70 (d, J = 8.7Hz, 2H), 7.11 (d, J = 8.6Hz, 2H), 7.04 (d, J = 8.6Hz, 2H), 3. 78-3.73(m,4H),3.25(dd,J=4.4,2.5Hz,4H),2.76-2.74(m,1H),2.34(ddd,J=9.9,6.6,3.4Hz,1H),1.43-1.36(m,1H),1.17(q,J=6.6Hz,1H); 13 C NMR(151MHz,DMSO)δ164.82,152.99,137.89,133.86,129.03,126.30,124.26, 120.23,113.47,65.85,47.39,30.37,20.34,13.04; MS-ESI(m / z):338.19(M+H) + .
[0087] Example 2, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-(4,4-dimethylpiperidin-1-yl)benzamide ((±)-1b)
[0088] According to the synthesis method of the above compound (±)-1a, 4-(4,4-dimethylaminopiperidin-1-yl)benzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid 1b (yield 49%). 1 H NMR (500MHz, DMSO) δ10.03(s,1H),8.53(s,3H),7.93(d,J=7.6Hz,2H),7.72(d,J=8.5Hz,2H),7.25(s,2H),7.14(d,J=8.3Hz,2H),3. 39(s,4H),2.78(s,1H),2.34(s,1H),1.55(s,4H),1.43-1.36(m,1H),1.19(q,J=6.7Hz,1H),1.02(s,6H); MS-ESI(m / z):364.24(M+H) + .
[0089] Example 3, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-cyclohexylbenzamide ((±)-1c)
[0090] According to the synthesis method of the above compound (±)-1a, 4-cyclohexylbenzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1c (yield 52%). 1 H NMR (500MHz, DMSO) δ10.14(s,1H),8.47(s,3H),7.87(d,J=7.0Hz,2H),7.71(d,J=7.3Hz,2H),7.36(d,J=7.4Hz,2H),7.13(d,J=7.4Hz,2H),2.77(s,1 H),2.59(t,J=11.3Hz,1H),2.32(s,1H),1.81(d,J=10.8Hz,4H),1.72(d,J =13.1Hz,1H),1.46-1.38(m,5H),1.30-1.24(m,1H),1.18(q,J=6.7Hz,1H); 13 C NMR (151MHz, DMSO) δ165.83,151.79,138.14,134.66,133.05,128.21,127.12,126.85 ,120.72,44.16,34.19,30.90,26.73,26.00,20.87,13.61; MS-ESI(m / z):335.21(M+H) + .
[0091] Example 4, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-isobutylbenzamide ((±)-1d)
[0092] According to the synthesis method of the above compound (±)-1a, 4-isobutylbenzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1d (yield 51%). 1 H NMR (500MHz, DMSO) δ10.15(s,1H),8.48(s,3H),7.87(d,J=7.2Hz,2H),7.71(d,J= 7.6Hz,2H),7.30(d,J=7.8Hz,2H),7.13(d,J=7.8Hz,2H),2.77(s,1H),2.53(d,J=6 .2Hz,2H),2.32(ddd,J=10.2,6.5,3.8Hz,1H),1.88(dt,J=13.9,7.1Hz,1H),1.38( dt,J=10.6,5.3Hz,1H),1.24(s,1H),1.18(q,J=6.5Hz,1H),0.88(d,J=6.2Hz,6H); 13 C NMR (151MHz, DMSO) δ165.80,145.55,138.13,134.69,132.90,129.37,128.02,126 .85,120.77,44.81,30.89,30.04,22.58,20.87,13.60; MS-ESI(m / z):309.20(M+H) + .
[0093] Example 5, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-vinylbenzamide ((±)-1e)
[0094] According to the synthesis method of the above compound (±)-1a, 4-vinylbenzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1e (yield 50%). 1 H NMR(600MHz,MeOD)δ7.90-7.88(m,2H),7.65-7.63(m,2H),7.58-7.56(m,2H),7 .19-7.16(m,2H),6.82(dd,J=17.6,10.9Hz,1H),5.92(dd,J=17.7,0.8Hz,1H), 5.37(dd,J=10.9,0.8Hz,1H),2.84(dt,J=7.9,4.1Hz,1H),2.37(ddd,J=10.2,6 .6,3.6Hz,1H),1.41(ddd,J=10.2,6.6,4.4Hz,1H),1.34(dt,J=7.9,6.6Hz,1H); 13C NMR(151MHz,MeOD)δ168.49,142.56,138.78,137.31,135.89,135.25,129.03,1 27.86,127.37,122.60,116.55,31.97,22.26,13.76; MS-ESI(m / z):279.15(M+H) + .
[0095] Example 6, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-(pyridin-4-yl)benzamide ((±)-1f)
[0096] According to the above synthesis method of compound (±)-1a, 4-pyridin-4-yl-benzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1f (yield 48%). 1 H NMR (600MHz, DMSO) δ10.50(s,1H),8.98(d,J=5.9Hz,2H),8.63(s,4H),8.40(d,J=4.9Hz,2H),8.19(dd,J=12.4,8.4Hz,4H) ,7.77(d,J=8.5Hz,2H),7.17(d,J=8.5Hz,2H),2.79-2.77(m,1H),2.38-2.35(m,1H),1.44-1.40(m,1H),1.21-1.17(m,1H); 13 C NMR(151MHz,DMSO)δ164.90,144.15,143.98,137.81,137.42,135.20,129.25,1 28.38,126.92,124.32,120.98,30.91,20.85,13.62; MS-ESI(m / z):330.16(M+H) + .
[0097] Example 7, trans-4-(4-fluorophenyl)-N-(4-(2-aminocyclopropyl)phenyl)-benzamide ((±)-1 g)
[0098] According to the synthesis method of the above compound (±)-1a, 4-(4-fluorophenyl)benzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1g (yield 47%). 1H NMR (600MHz, DMSO) δ10.31(s,1H),8.52(s,3H),8.07-8.05(m,2H),7.81(ddd,J=7.2,6.0,1.9Hz,4H),7.75-7.74(m,2H),7.36 -7.32(m,2H),7.16-7.15(m,2H),2.82-2.76(m,1H),2.34(ddd,J=10.0,6.3,3.6Hz,1H),1.41-1.38(m,1H),1.25-1.16(m,1H); 13 C NMR (151MHz, DMSO) δ165.40, 162.75 (d, J = 245.1Hz), 142.47, 138.03, 136.04, 134.86, 134.06, 129.46 (d, J = 8. 0Hz),128.84,126.98,126.89,120.85,116.36(d,J=21.5Hz),30.91,20.87,13.62; MS-ESI(m / z):347.16(M+H) + .
[0099] Example 8, trans-4-(4-trifluoromethylphenyl)-N-(4-(2-aminocyclopropyl)phenyl)-benzamide (1h)
[0100] According to the synthesis method of the above compound (±)-1a, 4-(4-trifluoromethylphenyl)benzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1h (yield 45%). 1 H NMR (600MHz, DMSO) δ10.33(s,1H),8.42(s,3H),8.10(d,J=8.4Hz,2H),7.99(d,J=8.2Hz,2H),7.92-7.90(m,2H),7.87(d,J=8. 4Hz,2H),7.76-7.74(m,2H),7.18-7.14(m,2H),2.80(s,1H),2.32(s,1H),1.38(p,J=5.2Hz,1H),1.21(dt,J=13.5,7.9Hz,1H); 13 C NMR (151MHz, DMSO) δ165.32,143,61,141.89,137.98,135.04,134.91,128.94,128.2 5,127.51,126.90,126.38,120.88,30.93,20.90,13.66; MS-ESI(m / z):397.15(M+H) + .
[0101] Example 9, trans-4-(4-methoxyphenyl)-N-(4-(2-aminocyclopropyl)phenyl)-benzamide ((±)-1i)
[0102] According to the above-mentioned synthesis method of compound (±)-1a, 4-(4-methoxyphenyl)benzoic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1i (yield 45%). 1 H NMR (600MHz, DMSO) δ10.24(s,1H),8.43(s,3H),8.02(d,J=8.5Hz,,2H),7.78(d,J=8.5Hz,2H),7.73(dd,J=13.3,8.7Hz,4H),7.15(d,J= 8.6Hz,2H),7.07(d,J=8.8Hz,2H),3.82(s,3H),2.79(s,1H),2.33-2.30(m,1H),1.38(ddd,J=10.3,6.1,4.4Hz,1H),1.22-1.18(m,1H); 13 C NMR (151MHz, DMSO) δ165.50,159.95,143.22,138.09,134.75,133.31,128.78,128.54 ,126.87,126.38,120.83,114.99,55.73,30.92,20.89,13.64; MS-ESI(m / z):359.18.
[0103] Example 10, trans-N-(4-(2-aminocyclopropyl)phenyl)-6-(4-methylpiperazinyl)-3-pyridinecarboxamide ((±)-1j)
[0104] According to the synthesis method of the above compound (±)-1a, 6-(4-methylpiperazinyl)-3-pyridinecarboxylic acid was used instead of 4-morpholinebenzoic acid to obtain a yellow solid (±)-1j (yield 47%). 1H NMR(600MHz,DMSO)δ11.17(s,1H),10.14(s,1H),8.80(s,1H),8.53(s,3H),8.22( d,J=9.0Hz,1H),7.71(d,J=8.4Hz,2H),7.14(d,J=8.4Hz,2H),7.07(d,J=9.0Hz,1H ),4.52(d,J=13.2Hz,2H),3.50(d,J=12.2Hz,2H),3.42-3.37(m,2H),3.14-3.03(m ,2H),2.84-2.75(m,4H),2.37-2.31(m,1H),1.43-1.37(m,1H),1.23-1.17(m,1H); 13 C NMR (151MHz, DMSO) δ138.24,138.01,134.74,126.85,120.83,120.41,52.13,42.39,42.15,30.87,20.83,13.57; MS-ESI(m / z):352.21(M+H) + .
[0105] Example 11, trans-N-(4-(2-aminocyclopropyl)phenyl)-benzamide ((±)-2a)
[0106] According to the synthesis method of the above compound (±)-1a, benzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2a (yield 65%). 1 H NMR (500MHz, DMSO) δ10.23(s,1H),8.49(s,3H),7.95(d,J=7.5Hz,2H),7.72(d,J=8.2Hz,2H),7.59(t,J=7.3Hz,1H),7.52(t,J =7.5Hz,2H),7.14(d,J=8.2Hz,2H),2.78(s,1H),2.33(ddd,J=9.9,6.2,3.5Hz,1H),1.39(dt,J=10.4,5.1Hz,1H),1.18(m,1H); 13 C NMR (151MHz, DMSO) δ165.37,137.53,134.88,134.34,131.51,128.34,127.60,126.38,120.34,30.40,20.36,13.11; MS-ESI(m / z):253.13(M+H) + .
[0107] Example 12, trans-N-(4-(2-aminocyclopropyl)phenyl)-2-bromobenzamide ((±)-2b)
[0108] According to the synthesis method of the above compound (±)-1a, 2-bromobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2b (yield 67%). 1 H NMR (500MHz, DMSO) δ10.45(d,J=4.1Hz,1H),8.58(s,3H),7.72(t,J=6.9Hz,1H),7.65(t,J=7.0Hz,2H),7.56-7.53(m,1H),7.52-7 .47(m,1H),7.47-7.39(m,1H),7.15(t,J=7.0Hz,2H),2.82-2.73(m,1H),2.42-2.32(m,1H),1.46-1.37(m,1H),1.22-1.14(m,1H); 13 C NMR(151MHz,DMSO)δ166.15,139.58,137.78,135.06,133.19,131.64,129.30,1 28.19,127.06,120.07,119.46,30.88,20.83,13.59; MS-ESI(m / z):331.04(M+H) + .
[0109] Example 13, trans-N-(4-(2-aminocyclopropyl)phenyl)-3-bromobenzamide ((±)-2c)
[0110] According to the synthesis method of the above compound (±)-1a, 3-bromobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2c (yield 69%). 1 H NMR (500MHz, DMSO) δ10.36(s,1H),8.52(s,3H),8.16(s,1H),7.98(d,J=7.8Hz,1H),7.81(d,J=7.9Hz,1H),7.72(d,J=8.3H z,2H),7.52(t,J=7.8Hz,1H),7.17(d,J=8.3Hz,2H),2.80(s,1H),2.39-2.32(m,1H),1.45-1.37(m,1H),1.24-1.18(m,1H); 13C NMR(151MHz,DMSO)δ164.27,137.71,137.49,135.15,134.75,131.12,130.68,1 27.32,126.92,122.15,120.93,30.91,20.86,13.63; MS-ESI(m / z):331.04(M+H) + .
[0111] Example 14, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-bromobenzamide ((±)-2d)
[0112] According to the synthesis method of the above compound (±)-1a, 4-bromobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2d (yield 67%). 1 H NMR (500MHz, DMSO) δ10.31(s,1H),8.45(s,3H),7.91(d,J=8.2Hz,2H),7.74(d,J=8.2Hz,2H),7.70(d,J=8.4Hz ,2H),7.15(d,J=8.4Hz,2H),2.78(s,1H),2.34-2.28(m,1H),1.38(dt,J=10.4,5.5Hz,1H),1.22-1.16(m,1H); 13 CNMR(151MHz,DMSO)δ164.87,137.81,135.03,134.40,131.87,130.26,126.90,125.79,120.89,30.92,20.87,13.64; MS-ESI(m / z):331.04(M+H) + .
[0113] Example 15, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-fluorobenzamide ((±)-2e)
[0114] According to the synthesis method of the above compound (±)-1a, 4-fluorobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2e (yield 65%). 1H NMR (500MHz, DMSO) δ10.30(s,1H),8.59(s,3H),8.06(dd,J=8.8,5.6Hz,2H),7.72(d,J=8.3Hz,2H),7.37(t,J=8.8Hz,2H),7.1 6(d,J=8.3Hz,2H),2.81-2.75(m,2H),2.36(ddd,J=10.0,6.4,3.6Hz,1H),1.42(dt,J=10.2,5.4Hz,1H),1.20(q,J=6.7Hz,1H); 13 C NMR (151MHz, DMSO) δ164.75, 164.52 (d, J = 248.8Hz), 137.92, 134.95, 131.77 (d, J = 3.0Hz), 130.86 (d ,J=8.9Hz),126.89,120.90,115.77(d,J=21.5Hz),30.90,20.84,13.60; MS-ESI(m / z):271.12(M+H) + .
[0115] Example 16, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-chlorobenzamide ((±)-2f)
[0116] According to the synthesis method of the above compound (±)-1a, 4-chlorobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2f (yield 65%). 1 H NMR (500MHz, DMSO) δ10.35(s,1H),8.59(s,3H),8.02(d,J=8.5Hz,2H),7.73(d,J=8.4Hz,2H),7.61(d,J=8.5Hz,2H),7.16 (d,J=8.4Hz,2H),2.78(s,1H),2.37(ddd,J=10.0,6.3,3.6Hz,1H),1.42(ddd,J=10.3,6.1,4.4Hz,1H),1.23-1.16(m,1H); 13 C NMR (151MHz, DMSO) δ164.75,137.81,136.83,135.06,134.03,130.10,128.91,126.90,120.92,30.90,20.84,13.60; MS-ESI(m / z):287.10(M+H) + .
[0117] Example 17, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-methylbenzamide ((±)-2 g)
[0118] According to the synthesis method of the above compound (±)-1a, 4-methylbenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2g (yield 67%). 1 H NMR (500MHz, DMSO) δ10.15(s,1H),8.56(s,3H),7.88(d,J=7.8Hz,2H),7.71(d,J=8.3Hz,2H),7.33(d,J=7.8Hz,2H),7.13( d,J=8.3Hz,2H),2.76(s,1H),2.38(s,3H),2.34(ddd,J=10.0,6.3,3.5Hz,1H),1.40(dt,J=10.2,5.4Hz,1H),1.18(m,1H); 13 C NMR(151MHz,DMSO)δ165.67,142.00,138.09,134.72,132.47,129.35,128.14,1 27.93,126.84,120.82,30.88,21.47,20.84,13.57; MS-ESI(m / z):267.15(M+H) + .
[0119] Example 18, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-ethylbenzamide ((±)-2h)
[0120] According to the synthesis method of the above compound (±)-1a, 4-ethylbenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2h (yield 70%). 1 H NMR (500MHz, DMSO) δ10.18(s,1H),8.59(s,3H),7.91(d,J=8.1Hz,2H),7.73(d,J=8.5Hz,2H),7.37(d,J=8.1Hz,2H),7.15(d,J=8.5Hz,2H),2.81-2. 76(m,1H),2.70(q,J=7.6Hz,2H),2.36(ddd,J=10.0,6.2,3.5Hz,1H),1.4 2(ddd,J=10.2,6.0,4.3Hz,1H),1.23(t,J=7.6Hz,3H),1.21-1.16(m,1H); 13C NMR(151MHz,DMSO)δ165.75,148.15,138.10,134.72,132.80,128.23,128.19, 126.85,120.80,30.88,28.53,20.84,15.85,13.57; MS-ESI(m / z):281.17(M+H) + .
[0121] Example 19, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-methoxybenzamide ((±)-2i)
[0122] According to the synthesis method of the above compound (±)-1a, 4-methoxybenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2i (yield 67%). 1 H NMR (500MHz, DMSO) δ10.06 (s, 1H), 8.45 (s, 3H), 7.95 (d, J = 8.7Hz, 2H), 7.70 (d, J = 8.3Hz, 2H), 7.13 (d, J = 8.3Hz, 2H),7.05(d,J=8.7Hz,2H),3.84(s,3H),2.77(s,1H),2.34-2.28(m,1H),1.40-1.34(m,1H),1.21-1.15(m,1H); 13 C NMR (151MHz, DMSO) δ165.23,162.35,138.21,134.53,130.03,127.38,126. 82,120.79,114.06,55.91,30.89,20.86,13.59; MS-ESI(m / z):283.14(M+H) + .
[0123] Example 20, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-trifluoromethoxybenzamide ((±)-2j)
[0124] According to the synthesis method of the above compound (±)-1a, 4-trifluoromethoxybenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2j (yield 67%). 1H NMR (500MHz, DMSO) δ10.38(s,1H),8.53(s,3H),8.11(d,J=8.4Hz,2H),7.72(d,J=8.3Hz,2H),7.54(d,J=8.3 Hz,2H),7.17(d,J=8.3Hz,2H),2.83-2.77(m,1H),2.39-2.32(m,1H),1.45-1.38(m,1H),1.24-1.17(m,1H); 13 CNMR(151MHz,DMSO)δ164.65,150.91,137.80,135.08,134.49,130.52,126.92,121. 15,120.87,120.46(q,J=257.1Hz),30.91,20.86,13.63; MS-ESI(m / z):337.12(M+H) + .
[0125] Example 21, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-nitrobenzamide ((±)-2k)
[0126] According to the synthesis method of the above compound (±)-1a, 4-nitrobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2k (yield 64%). 1 H NMR (500MHz, DMSO) δ10.55(s,1H),8.39-8.31(m,5H),8.18(d,J=8.5Hz,2H),7.71(d,J=8.3Hz,2 H),7.17(d,J=8.3Hz,2H),2.81(s,1H),2.33-2.27(m,1H),1.39-1.33(m,1H),1.22-1.18(m,1H); 13 C NMR (151MHz, DMSO) δ164.21,149.63,141.00,137.55,135.43,129.68,126.98,124.02,120.98,30.95,20.89,13.69; MS-ESI(m / z):298.12(M+H) + .
[0127] Example 22, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-trifluoromethylbenzamide ((±)-21)
[0128] According to the synthesis method of the above compound (±)-1a, 4-trifluoromethylbenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-21 (yield 67%).1 H NMR (500MHz, DMSO) δ10.47(s,1H),8.47(s,3H),8.15(d,J=8.1Hz,2H),7.91(d,J=8.1Hz,2H),7.72(d,J=8.5H z,2H),7.16(d,J=8.5Hz,2H),2.82-2.76(m,1H),2.37-2.30(m,1H),1.42-1.36(m,1H),1.20(q,J=6.7Hz,1H); 13 C NMR (151MHz, DMSO) δ164.70,139.16,137.67,135.26,129.06,126.95,125.85(q,J=3.4Hz),120.94,30.93,20.88,13.67; MS-ESI(m / z):321.12(M+H) + .
[0129] Example 23, trans-N-(4-(2-aminocyclopropyl)phenyl)-4-cyanobenzamide ((±)-2m)
[0130] According to the synthesis method of the above compound (±)-1a, 4-cyanobenzoyl chloride was used instead of 4-morpholinebenzoic acid for direct condensation to obtain a yellow solid (±)-2m (yield 71%). 1 H NMR (500MHz, DMSO) δ10.50(s,1H),8.52(s,3H),8.11(d,J=8.1Hz,2H),8.02(d,J=8.0Hz,2H),7.72(d,J=8.2Hz ,2H),7.16(d,J=8.2Hz,2H),2.78(s,1H),2.38-2.30(m,1H),1.44-1.36(m,1H),1.19(dd,J=13.5,6.6Hz,1H); 13 C NMR(151MHz,DMSO)δ164.45,139.35,137.59,135.36,132.92,129.00,126.9 5,120.95,118.79,114.29,30.92,20.86,13.65; MS-ESI(m / z):278.13(M+H) + .
[0131] Example 24, trans-4-bromo-N-(4-(2-(methylamino)cyclopropyl)phenyl)-benzamide ((±)-3a)
[0132] At room temperature, paraformaldehyde (0.55 mmol) and glacial acetic acid (2 mmol) were added to a methanol solution of (±)-2d (0.5 mmol), and the mixture was stirred under reflux for 1 h. After cooling to room temperature, sodium cyanoborohydride (1 mmol) was added, and the mixture was stirred at room temperature for 4 h. The mixture was quenched with aqueous sodium hydroxide solution, extracted with ethyl acetate, dried with magnesium sulfate, filtered, and the filtrate was concentrated and purified by preparative chromatography (dichloromethane: methanol = 10:1) to obtain a yellow oil 4a (yield 41%). 1 H NMR(500MHz,MeOD)δ7.39(d,J=8.0Hz,2H),7.21(d,J=8.1Hz,2H),7.10-6.92(m,4H),3.45(s,3H),2 .49-2.43(m,1H),1.87(ddd,J=9.3,5.8,3.2Hz,1H),1.07(dt,J=9.7,4.9Hz,1H),1.01-0.96(m,1H); 13 C NMR (151MHz, MeOD) δ171.81,143.03,136.43,132.10,131.35,128.11,127.59,124.95,38.76,36.03,25.79,18.33; MS-ESI(m / z):345.06(M+H) + .
[0133] Example 25, trans-4-bromo-N-(4-(2-(dimethylamino)cyclopropyl)phenyl)-benzamide ((±)-3b)
[0134] According to the synthesis method of the above compound (±)-3a, paraformaldehyde was added and the reaction was carried out overnight to obtain a yellow solid 4b (yield 47%). 1 H NMR (500MHz, DMSO) δ10.22(s,1H),7.91(d,J=8.3Hz,2H),7.75(d,J=8.3Hz,2H),7.64(d,J=8.4 Hz,2H),7.08(d,J=8.4Hz,2H),2.29(s,6H),1.90(m,1H),1.75-1.70(m,1H),1.03-0.92(m,2H); 13 C NMR (151MHz, DMSO) δ164.74,138.05,136.96,134.55,131.82,130.20,126.39,120.94,50.60,45.04,24.72,17.09; MS-ESI(m / z):359.08(M+H) + .
[0135] Example 26, trans-4-bromo-N-(4-(2-(piperidin-4-amino)cyclopropyl)phenyl)-benzamide ((±)-3c)
[0136] According to the synthesis method of the above compound (±)-3a, N-tert-butyloxycarbonyl-4-piperidone was used instead of paraformaldehyde and deprotected to obtain a white solid (±)-3c (yield 47%). 1 H NMR (500MHz, DMSO) δ10.37(s,1H),10.06(s,2H),9.27(d,J=9.5Hz,1H),8.98(d,J=10. 2Hz,1H),7.94(d,J=8.5Hz,2H),7.75(dd,J=10.8,8.6Hz,4H),7.20(d,J=8.5Hz,2H),3. 52(s,1H),3.40(d,J=10.9Hz,2H),2.95(m,3H),2.61(ddd,J=10.1,6.4,3.5Hz,1H),2. 27(d,J=12.8Hz,2H),1.96(m,2H),1.62(dt,J=10.4,5.3Hz,1H),1.30(q,J=6.7Hz,1H); 13 C NMR (151MHz, DMSO) δ164.89,137.99,134.45,134.42,131.84,130.27,127.10,125.76 ,121.06,53.15,41.83,35.53,25.48,25.39,20.63,12.86; MS-ESI(m / z):416.12(M+H) + .
[0137] Example 27, trans-N-(4-(2-((4-aminocyclohexyl)amino)cyclopropyl)phenyl)-4-bromobenzamide ((±)-3d)
[0138] According to the synthesis method of the above compound (±)-3a, 4-N-Boc-aminocyclohexanone was used to replace paraformaldehyde and deprotected to obtain a white solid (±)-3d (yield 37%). 1H NMR (500MHz, DMSO) δ10.35 (s, 1H), 9.66 (s, 2H), 8.13 (s, 3H), 7.94 (d, J = 8.3Hz, 2H),7.75(dd,J=14.8,8.3Hz,4H),7.18(d,J=8.3Hz,2H),3.19(s,1H),2.99(s, 1H),2.90(s,1H),2.59-2.53(m,1H),2.20(s,2H),2.06(d,J=12.2Hz,2H),1.62 -1.49(m,3H),1.47-1.37(m,2H),1.33-1.24(m,1H); MS-ESI(m / z):428.13(M+H) + .
[0139] 3.5 Synthesis of target compounds IV-4e~i
[0140] Example 28, trans-4-bromo-N-(4-(2-(methylsulfonamido)cyclopropyl)phenyl)benzamide ((±)-3e)
[0141] To a solution of (±)-2d (0.3 mmol) in acetonitrile was added triethylamine (0.5 mmol) and methanesulfonyl chloride (0.36 mmol) at room temperature, and the mixture was stirred for 2 h at the same temperature. The mixture was purified by column chromatography (dichloromethane:methanol=20:1) to give 4e as a white solid (yield 67%). 1 H NMR (500MHz, DMSO) δ10.29(s,1H),7.95(d,J=8.4Hz,2H),7.79(d,J=8.4Hz,2H),7.70(d,J=8.3Hz,2H),7.61(d,J=2. 8Hz,1H),7.16(d,J=8.3Hz,2H),3.01(s,3H),2.70-2.63(m,1H),2.18-2.12(m,1H),1.29(s,3H),1.27-1.18(m,2H); 13 C NMR (151MHz, DMSO) δ164.79,137.36,136.57,134.47,131.86,130.23,126.59,125.73,120.89,34.49,23.70,15.31; MS-ESI(m / z):411.02(M+H) + .
[0142] Example 29, trans-N-(4-(2-acetylaminocyclopropyl)phenyl)-4-bromobenzamide ((±)-3f)
[0143] According to the synthesis method of the above compound (±)-3e, acetyl chloride was used instead of methanesulfonyl chloride to obtain a yellow-white solid IV-4f (yield 77%). 1 H NMR (500MHz, DMSO) δ10.25(s,1H),8.13(d,J=4.3Hz,1H),7.92(d,J=8.5Hz,2H),7.76(d,J=8.5Hz,2H),7.66(d, J=8.6Hz,2H),7.10(d,J=8.6Hz,2H),2.83-2.75(m,1H),1.93-1.88(m,1H),1.82(s,3H),1.12(t,J=7.0Hz,2H); 13 C NMR(151MHz,DMSO)δ170.52,164.76,137.43,137.11,134.50,131.84,130.22,1 26.42,125.69,120.84,32.89,23.96,23.00,15.53; MS-ESI(m / z):373.06(M+H) + .
[0144] Example 30, trans-4-bromo-N-(4-(2-propionylaminocyclopropyl)phenyl)-benzamide ((±)-3 g)
[0145] According to the above-mentioned synthesis method of compound (±)-3e, propionyl chloride was used instead of methanesulfonyl chloride to obtain a yellow solid (±)-3g (yield 77%). 1 H NMR (500MHz, DMSO) δ10.23(s,1H),8.02(d,J=3.9Hz,1H),7.90(d,J=8.3Hz,2H),7.74(d,J=8.3Hz,2H),7.64(d,J=8.2Hz,2H), 7.09(d,J=8.2Hz,2H),2.81-2.75(m,1H),2.06(q,J=7.6Hz,2H),1.92-1.85(m,1H),1.14-1.07(m,2H),0.99(t,J=7.6Hz,3H); 13 C NMR (151MHz, DMSO) δ174.22,164.76,137.46,137.10,134.51,131.84,130.22,126. 45,125.69,120.83,32.83,28.77,23.98,15.60,10.25; MS-ESI(m / z):387.07(M+H) + .
[0146] Example 31, trans-4-bromo-N-(4-(2-(3-methylureido)cyclopropyl)phenyl)-benzamide ((±)-3h)
[0147] According to the synthesis method of the above compound (±)-3e, methylaminocarbonyl chloride was used instead of methanesulfonyl chloride to obtain a yellow solid (±)-3h (yield 70%). 1 H NMR (500MHz, DMSO) δ10.24(s,1H),7.92(d,J=8.4Hz,2H),7.76(d,J=8.4Hz,2H),7.66(d,J=8.3Hz,2H),7.09(d,J=8.4Hz,2H),6.33(d ,J=2.6Hz,1H),5.71(q,J=4.6Hz,1H),2.64-2.59(m,1H),2.57(d,J=4.6Hz,3H),1.88(ddd,J=9.4,6.4,3.2Hz,1H),1.12-1.02(m,2H); 13 C NMR(151MHz,DMSO)δ164.75,159.51,137.69,137.01,134.51,131.84,130.22,1 26.46,125.69,120.81,33.40,26.88,24.65,16.52; MS-ESI(m / z):388.07(M+H) + .
[0148] Example 32, trans-N-(-2-(4-(4-bromobenzamido)phenyl)cyclopropyl)piperazine-1-amide ((±)-3i)
[0149] According to the synthesis method of the above compound (±)-3e, 4-BOC-1-piperazinecarbonyl chloride was used instead of methanesulfonyl chloride for deprotection to obtain a yellow-white solid (±)-3i (yield 67%). 1 H NMR (500MHz, DMSO) δ10.27(s,1H),9.26(s,2H),7.92(d,J=8.2Hz,2H),7.73(d,J=8.2Hz,2H),7.65(d,J=8.2Hz,2H),7.10(s,1H),7.09(s,2H) ,3.53(t,J=5.2Hz,4H),3.03(s,4H),2.72-2.65(m,1H),1.90(ddd,J=9.4,6.4,3.2Hz,1H),1.16(dt,J=9.4,5.0Hz,1H),1.08(q,J=6.4Hz,1H); 13C NMR (151MHz, DMSO) δ164.77,158.01,137.69,137.07,134.54,131.81,130.24,126. 58,125.65,120.89,42.95,40.95,34.08,24.21,15.73; MS-ESI(m / z):445.11(M+H) + .
[0150] Example 33, trans-2-(4-(4-bromobenzamido)phenyl)cyclopropane-1-carboxylic acid ethyl ester ((±)-3j)
[0151]
[0152] Under argon protection, 5% palladium on carbon was added to a solution of (±)-6 (0.23 mmol) in methanol (10 mL), and the mixture was replaced with hydrogen. The reaction was stirred at room temperature for 1 h, replaced with argon, filtered through celite, and the filtrate was concentrated. The filtrate was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain a yellow oil (±)-7.
[0153] To a solution of (±)-7 (0.5 mmol) and N,N-diisopropylethylamine (1 mmol) in anhydrous tetrahydrofuran was added 4-bromobenzoyl chloride (0.55 mmol) at room temperature, and the reaction was stirred at the same temperature overnight. The mixture was quenched with water, extracted with dichloromethane, dried with magnesium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (dichloromethane: methanol = 50:1) to obtain a white solid (±)-3j (yield 65%). 1 HNMR (500MHz, CDCl3) δ7.74(s,1H),7.73-7.69(m,2H),7.63(d,J=8.5Hz,1H),7.53(d,J=8.4Hz,2H),7.11(d,J=8.4Hz,2H),4.18(q ,J=7.1Hz,2H),2.52(ddd,J=9.7,6.5,4.1Hz,1H),1.88(dt,J=8.9,4.8Hz,1H),1.60(dd,J=9.7,4.8Hz,1H),1.29(t,J=7.1Hz,4H); 13 CNMR(151MHz,CDCl3)δ173.34,164.61,136.70,136.08,133.73,132.07,128.61,126 .97,126.63,120.40,60.76,25.75,24.11,16.95,14.28; MS-ESI(m / z):388.05(M+H) + .
[0154] Example 34, trans-2-(4-(4-bromobenzamido)phenyl)cyclopropane-1-carboxylic acid ((±)-3k)
[0155]
[0156] To (±)-3j (0.3 mmol) tetrahydrofuran and water (V 3:1 ) was added with lithium hydroxide (0.45 mmol) and stirred at room temperature overnight. The pH was adjusted to 3 with 1 M dilute hydrochloric acid solution. The precipitated white solid was (±)-3k (yield 75%). 1 H NMR (500MHz, DMSO) δ12.23(s,1H),10.25(s,1H),7.90(d,J=8.4Hz,2H),7.74(d,J=8.4Hz,2H),7.67(d,J=8.5Hz,2H),7.15 (d,J=8.5Hz,2H),2.37(m,1H),1.78(dt,J=8.9,4.7Hz,1H),1.41(dt,J=9.3,4.7Hz,1H),1.33(ddd,J=8.4,6.5,4.7Hz,1H); 13 C NMR(151MHz,DMSO)δ174.41,164.84,137.69,136.09,134.46,131.86,130.2 4,126.62,125.75,120.88,25.50,24.57,16.97; MS-ESI(m / z):360.02(M+H) + .
[0157] Chiral separation example 1, compound (±)-2d
[0158] The target compound was separated by high performance liquid chromatography and semi-preparative high performance liquid chromatography. The anti-racemic compound was dissolved in a mixed solution of chromatographic ethanol: methanol: n-hexane = 50:20:30 (v / v / v) to prepare a saturated solution.
[0159] The samples were first screened for separation conditions on an Agilent 1260 HPLC-UV system. Conditions (solvent A = 0.1% n-butylamine + n-hexane, solvent B = 0.1% n-butylamine + isopropanol): Daicel AS-H analytical column (150 mm × 4.6 mm, 5 μm). Injection volume: 5 μL. Flow rate: 3.76 mL / min. Mobile phase: 60% A, 40% B. UV at 254 nm, column temperature 25°C.
[0160] The instrument used for the preparation of the liquid phase was Thermo UltiMate 3000 HPLC-UV. Separation conditions (solvent A = 0.1% n-butylamine + n-hexane, solvent B = 0.1% n-butylamine + isopropanol): Daicel AS-H semi-preparative column (250 mm×4.6 mm, 10 μm). Injection volume: 300 μL. Flow rate: 3.76 mL / min.
[0161] Mobile phase: 65% A, 35% B. UV at 254nm, column temperature 25°C. The structure is as follows.
[0162]
[0163] Results of chiral separation of compound (±)-2d
[0164] Other compounds can be separated according to the idea of this method.
[0165] Biological Activity Example 1 Anti-coronavirus HCoV-OC43 Activity Experiment of Compounds 1a-j
[0166] HCT-8 cells were expressed at 1.0×10 4 Cells were inoculated in 96-well plates at 100 μL per well. The cell culture medium was DMEM medium containing 10% FBS and cultured for 48 hours. The supernatant was discarded and replaced with fresh DMEM medium containing 2% FBS. HCoV-OC43 (ATCC: VR-1558) virus was infected at MOI = 0.1. 1 μL of gradient dilutions of compounds containing cyclopropyl skeletons (final concentration was diluted 2-fold from 25 μM, 7 gradients were diluted) was added to each well, 1 μL of DMSO (dimethyl sulfoxide) was added to each well of the negative control group, and 1 μL of the broad-spectrum antiviral nucleoside inhibitor Remdesivir was used as a positive control (final concentration was diluted 2-fold from 25 μM, 7 gradients were diluted) was added to each well, and then cultured at 33°C for 60 hours. 20 μL of Cell Proliferation ColorimetricAssay (MTS) reagent was added and acted at 37°C for 3 hours. Finally, the absorption peak generated at a wavelength of 490 nm was detected. The calculation formula of inhibition rate (relative infectivity) was: inhibition rate = (virus group - sample group) / (virus group - blank group) × 100%. GraphPadPrism 5.0 was used for statistical analysis to obtain EC 50. The results are shown in Table 1.
[0167] Table 1 Anti-HCoV-OC43 activity of compounds 1a-j
[0168]
[0169] a HEK293T cells;b BHK21 cells.
[0170] Biological Activity Example 2 Anti-HCoV-OC43 Activity Experiment of Compound 2a-m
[0171] HCT-8 cells were expressed at 1.0×10 4 Cells were inoculated in 96-well plates at 100 μL per well. The cell culture medium was DMEM medium containing 10% FBS and cultured for 48 hours. The supernatant was discarded and replaced with fresh DMEM medium containing 2% FBS. HCoV-OC43 (ATCC: VR-1558) virus was infected at MOI = 0.1. 1 μL of gradient dilutions of compounds containing cyclopropyl skeletons (final concentration was diluted 2-fold from 25 μM, 7 gradients were diluted) was added to each well, 1 μL of DMSO (dimethyl sulfoxide) was added to each well of the negative control group, and 1 μL of the broad-spectrum antiviral nucleoside inhibitor Remdesivir was used as a positive control (final concentration was diluted 2-fold from 25 μM, 7 gradients were diluted) was added to each well, and then cultured at 33°C for 60 hours. 20 μL of Cell Proliferation ColorimetricAssay (MTS) reagent was added and acted at 37°C for 3 hours. Finally, the absorption peak generated at a wavelength of 490 nm was detected. The calculation formula of the inhibition rate (relative infectivity) is: inhibition rate = (virus group - sample group) / (virus group - blank group) × 100%. GraphPadPrism 5.0 was used for statistical analysis to obtain EC50. The results are shown in Table 2.
[0172] Table 2 Anti-HCoV-OC43 activity of compounds 2a-m
[0173]
[0174] a HEK293T cells; b BHK21 cells; NT: not tested.
[0175] Biological Activity Example 3 Anti-HCoV-OC43 Activity Experiment of Compounds 3a-k
[0176] HCT-8 cells were expressed at 1.0×10 4Cells were inoculated in 96-well plates at 100 μL per well. The cell culture medium was DMEM medium containing 10% FBS and cultured for 48 hours. The supernatant was discarded and replaced with fresh DMEM medium containing 2% FBS. HCoV-OC43 (ATCC: VR-1558) virus was infected at MOI = 0.1. 1 μL of gradient dilutions of compounds containing cyclopropyl skeletons (final concentration was diluted 2-fold from 25 μM, 7 gradients were diluted) was added to each well, 1 μL of DMSO (dimethyl sulfoxide) was added to each well of the negative control group, and 1 μL of the broad-spectrum antiviral nucleoside inhibitor Remdesivir was used as a positive control (final concentration was diluted 2-fold from 25 μM, 7 gradients were diluted) was added to each well, and then cultured at 33°C for 60 hours. 20 μL of Cell Proliferation ColorimetricAssay (MTS) reagent was added and acted at 37°C for 3 hours. Finally, the absorption peak generated at a wavelength of 490 nm was detected. The calculation formula of inhibition rate (relative infectivity) is: inhibition rate = (virus group - sample group) / (virus group - blank group) × 100%. GraphPadPrism 5.0 was used for statistical analysis to obtain EC50. The results are shown in Table 3.
[0177] Table 3 Anti-HCoV-OC43 activity of compounds 3a-k
[0178]
[0179]
[0180] a HEK293T cells; b BHK21 cells; NT: not tested.
[0181] Biological Activity Example 4 Anti-ZIKV Activity of Compounds 1a-j
[0182] Vero cells from non-human primates were used as sensitive cells, and ZIKV SZ-WIV01 (Genbank accession number: KU963796) isolated from imported cases at my country's ports in 2016 was used as the infection strain. First, the above cells were inoculated into a 96-well plate, and 70-80% of the cells were confluent after 24 hours; the test compound was further diluted in DMEM culture medium containing 2% FBS and inoculated onto the cells in the 96-well plate, and an equal volume of DMEM culture medium containing 2% FBS was added to the negative control well; the 96-well plate was placed in a 37°C carbon dioxide incubator for 7 days (vero cells), and the cell activity was determined using Luminescent Cell Viability Assay (Promega), and the drug's TC0, TC50, and TC90 were calculated based on the determination results. On this basis, the antiviral activity of the compounds was evaluated: first, the cells were inoculated into a 96-well plate, and after 24 hours, the cells were 70-80% confluent; the maximum non-toxic concentration (TC0) of the compound was used as the dilution starting point, and the test compound was diluted in multiples using DMEM culture medium containing 2% FBS; further, 100 times the half tissue infection dose of the virus (100TCID50) was used to infect the compound group and the negative control group cells, and at the same time, different concentrations of the compounds were added to the test wells, and no virus or compound was added to the cell control wells; the 96-well plate was placed in a 37°C carbon dioxide incubator and cultured for 7 days, and the cell activity was determined using the Luminescent Cell Viability Assay. According to the measurement results, the dose-effect relationship was fitted using Origin software, and the EC50 of each compound was calculated. The results are shown in Table 4.
[0183] Table 4 Anti-ZIKV activity of compounds 1a-j
[0184]
[0185] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. Cyclopropylamine compounds of the structure shown in Formula I, their pharmaceutically acceptable salts, enantiomers, diastereomers, optical isomers or racemates: in, X represents C or N; R 1 is one or more, independently representing H, halogen, cyano, NO2, C1-C5 alkyl, 1-3 halogenated C1-C5 alkyl, C1-C5 alkoxy, 1-3 halogenated C1-C5 alkoxy, C2-C5 alkenyl, C2-C5 alkynyl, R a Substituted or unsubstituted phenyl, R a Substituted or unsubstituted 5-6 membered cycloalkyl, R a Substituted or unsubstituted 5-6 membered heteroaryl, R a A substituted or unsubstituted 5-6 membered heterocyclic group containing 1-3 groups selected from N, O and S; R a is one or more than two, independently representing halogen, C1-C5 alkyl, 1-3 halogenated C1-C5 alkyl, C1-C5 alkoxy, 1-3 halogenated C1-C5 alkoxy; R 2 Represents NR x R y , C1-C5 carboxyl, C1-C5 ester, R x Selected from H, C1-C5 alkyl; R y Selected from H, C1-C5 alkyl, C1-C3 sulfonyl, C1-C5 carbonyl, C1-C5 substituted or unsubstituted aminoacyl.
2. The cyclopropylamine compound of formula I, its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate according to claim 1, characterized in that: The halogen is selected from F, Cl, Br, I; The C1-C5 alkyl group is selected from —CH3, —CH2CH3, —CH(CH3)2, —(CH2)2CH3, —(CH2)3CH3, —CH2CH(CH3)2, —C(CH3)3, —CH(CH3)CH2CH3, —(CH2)4CH3, —CH(CH3)(CH2)2CH3, —CH(CH2CH3)2, —CH2C(CH2)3, —CH2CH(CH3)CH2CH3, —C(CH3)2CH2CH3, —CH(CH3)CH(CH3)2, —(CH2)2CH(CH3)2; The C1-C5 alkoxy group is selected from -OCH3, -OCH2CH3, -OCH(CH3)2, -O(CH2)2CH3, -O(CH2)3CH3, -OCH2CH(CH3)2, -OC(CH3)3, -OCH(CH3)CH2CH3, -O(CH2)4CH3, - OCH(CH3)(CH2)2CH3, —OCH(CH2CH3)2, —OCH2C(CH2)3, —OCH2CH(CH3)CH2CH3, —OC(CH3)2CH2CH3, —OCH(CH3)CH(CH3)2, —O(CH2)2CH(CH3)2; The C2-C5 alkenyl group is selected from -CHCH2, -CH2CHCH2, -CHCHCH3, -CH2CHCHCH3, ―CHCHCH2CH3, ―CH2CH2CHCH2, ―CH(CH3)CHCH2, ―CH2CHCHCH2CH3, ―CHCHCH2CH2CH3, ―CH2CH2CHCHCH3, ―CH2CH2CH2CHCH2, ―CH(CH3)CHCHCH3; The C2-C5 alkynyl group is selected from -CCH, -CCCH3, -CH2CCH, -CCCH2CH3, -CH2CCCH3, -CH2CH2CCH, -CCCH2CH2CH3, -CH2CCCH2CH3, -CH2CH2CCCH3, -CH2CH2CH2CC H, -CH(CH3)CCCH3, -CH(CH3)CCH;. The 5-6 membered cycloalkyl group is selected from cyclohexyl and cyclopentyl; The 5-6 membered heteroaryl group is selected from pyridine, furan, pyrrole, thiophene, and thiazole; The 5-6 membered heterocyclic group is selected from piperidine, morpholine and piperazine; C1-C5 carboxyl is selected from: -C(O)OH, -CH2C(O)OH, -(CH2)2C(O)OH, -(CH2)3C(O)OH, ―(CH2)4C(O)OH; C1-C5 ester group is selected from: -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9, ―CH2C(O)OCH3, ―CH2C(O)OC2H5, ―CH2C(O)OC3H7, ―C2H4C(O)OCH3, ―C2H4C(O)OC2H5, ―C3H6C(O)OCH3; C1-C3 sulfonyl is selected from the group consisting of sulfonyl, methylsulfonyl, ethylsulfonyl, and propylsulfonyl; C1-C5 carbonyl is selected from: -C(O)CH3, -C(O)C2H5, -C(O)C3H7, -C(O)C4H9, CH2C(O)CH3, -CH2C(O)C2H5, -CH2C(O)C3H7, -(CH2)2C(O)CH3, -(CH2)2C(O)C2H5 or -(CH2)3C(O)CH3; The C1-C5 substituted or unsubstituted aminoacyl group is selected from: -C(O)NH2, -C(O)NHCH3, -C(O)NHC2H5, ―C(O)NHC3H7, ―C(O)NHC4H9, ―C(O)N(CH3)2, ―C(O)N(CH2CH3)2.
3. The cyclopropylamine compound of formula I according to claim 1, its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate, characterized in that: The R 1 Selected from H, Br, F, Cl, CF3, CH3, CH2CH3, OCF3, OCH3, NO2, CN, 4. The cyclopropylamine compound of formula I, its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate according to claim 1, characterized in that: The R 2 Selected from COOH, C(O)OCH2, C(O)OC2H5, NH2, NHCH3, N(CH3)2, 5. The cyclopropylamine compound of formula I, its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate according to claim 1, characterized in that: The pharmaceutically acceptable salt is selected from hydrochloride, phosphate, methanesulfonate, sulfate or malate.
6. The cyclopropylamine compound of formula I or its pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate according to claim 1, characterized in that: Selected from:
7. A method for preparing the compound according to claim 1, characterized in that: Choose from any of the following routes: Route 1 Step a: Compound (±)-4 and R 1 The substituted benzoic acid was refluxed in oxalyl chloride, DMF and DCM for 5-8 h, and then DIEA was added to react in THF overnight to obtain compound (±)-5; Step b: reacting with R-substituted benzoic acid under PyBOP condensing agent and alkaline conditions overnight to obtain compound (±)-5; Step c: Compound (±)-5 is dissolved in methanol, and the Boc protecting group is removed in the presence of hydrochloric acid and ether to obtain the target compound (±)-1-2; Route 2 Step a: Add paraformaldehyde and glacial acetic acid to a methanol solution of compound (±)-2d, reflux and stir for 1-2 hours, cool and add sodium cyanoborohydride, and cook at room temperature for 3-6 hours; Step b: Compound (±)-2d and R 2 Substituted acyl chloride or sulfonyl chloride is condensed under alkaline conditions to prepare compound (±)-3. Route 3 Step a: Compound (±)-6 is subjected to hydrogenation reduction to obtain compound (±)-7; Step b: Compound (±)-7 is condensed with 4-bromobenzoyl chloride to obtain the target compound (±)-3j; Step c: To a solution of (±)-3j in tetrahydrofuran and water was added lithium hydroxide and stirred at room temperature overnight.
8. A pharmaceutical composition comprising a cyclopropylamine compound of the structure shown in formula I according to any one of claims 1 to 6, a pharmaceutically acceptable salt, enantiomer, diastereomer, optical isomer or racemate thereof, and optionally, one or more pharmaceutically acceptable carriers or excipients.
9. Use of the cyclopropylamines of formula I, pharmaceutically acceptable salts, enantiomers, diastereomers, optical isomers or racemates thereof in the preparation of antiviral drugs according to any one of claims 1 to 6.
10. The use according to claim 9, characterized in that: The antiviral is selected from anti-coronavirus, anti-dengue virus, anti-Zika virus, anti-Ebola virus, or anti-influenza virus.
